Bank Julius Baer & Co. Ltd, Zurich Aldeyra Therapeutics, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$3.25 - $5.17 $11,375 - $18,095	-3,500 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$7.94 - $11.31 $238 - $339	-30 Reduced 0.85%	3,500 $31,000
Q2 2021 Jul 23, 2021	BUY	$10.44 - $14.85 $313 - $445	30 Added 0.86%	3,530 $40,000
Q1 2021 May 10, 2021	BUY	$6.53 - $14.42 $6,673 - $14,737	1,022 Added 41.24%	3,500 $42,000
Q4 2020 Feb 24, 2021	BUY	$6.31 - $8.13 $7,584 - $9,772	1,202 Added 94.2%	2,478 $17,000
Q4 2020 Feb 12, 2021	SELL	$6.31 - $8.13 $7,723 - $9,951	-1,224 Reduced 48.96%	1,276 $17,000
Q3 2020 Nov 10, 2020	BUY	$4.0 - $7.53 $10,000 - $18,825	2,500 New	2,500 $19,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $283M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.